Jason Aryeh
CIK 1376960 · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$51.27M
Companies
11
Total Filings
177
Lifetime Open-Market Net
-$34.25M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OBIO | Director | 118,118 | $4.24 | $500.8K | $39.9K | 13 | 2026-06-25 |
| LGND | Director | 120,580 | $293.15 | $35.35M | -$31.81M | 67 | 2026-06-12 |
| LFCR | Director | 69,967 | $5.01 | $350.5K | $0 | 3 | 2026-06-05 |
| Anebulo Pharmaceuticals, Inc. (ANEB) Delisted | Director | — | $0.36 | — | $0 | 3 | 2025-04-07 |
| MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | 10%+ Owner | 3,802 | $15.13 | $57.5K | $21.5K | 2 | 2019-07-18 |
| Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Director | 15,000 | — | — | $1.17M | 4 | 2017-05-24 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | 369,924 | — | — | $3.2K | 2 | 2017-05-17 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | — | — | — | $0 | 1 | 2017-01-10 |
| QLTI | Director | 535,478 | $28.14 | $15.07M | $1.05M | 18 | 2016-06-21 |
| Myrexis, Inc. (MYRX) Delisted | Director | 9,900 | — | — | $1.15M | 19 | 2012-06-20 |
| Vaxart, Inc. (NABI) Delisted | Director | 21,964 | — | — | -$5.87M | 39 | 2011-05-27 |
Recent Filings · Page 6 of 18
177 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-09 | LGND | Sell (S) | −7,500 | -$1.32M | EDGAR |
| 2018-02-27 | LGND | Mixed | −4,417 | -$529.6K | EDGAR |
| 2017-11-20 | LGND | Sell (S) | −24,400 | -$3.42M | EDGAR |
| 2017-08-25 | LGND | Sell (S) | −2,000 | -$256.0K | EDGAR |
| 2017-05-26 | LGND | Grant (A) | +666 | $0 | EDGAR |
| 2017-05-24 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Sell (S) | −388,685 | -$558.8K | EDGAR |
| 2017-05-17 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Buy (P) | +361 | $3.2K | EDGAR |
| 2017-05-12 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Grant (A) | +7,500 | $0 | EDGAR |
| 2017-05-12 | LGND | Sell (S) | −37,247 | -$4.13M | EDGAR |
| 2017-04-25 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Buy (P) | +295,929 | $1.73M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.